Post by
rixpix on Apr 16, 2021 11:34am
SVA Fair value is $2.08 according to MS
Morningstar has a 3 star rating and is showing Sernova shares as being Undervalued with the fair value being $2.08.
I'm happy being undervalued.
Comment by
HiFinance on Apr 16, 2021 11:43am
I rarely participate in discussions but I noticed in that same Morningstar report that 2021 YTD Capital Spending (K) -1,006 is already equal to all of 2020's Capital Spending. Where did Spend go and so quickly? I haven't read of any significant Projects announced so far this year.
Comment by
BioTeck on Apr 16, 2021 11:53am
Great questions for management. I know some of it went to Dominic's promotion. The rest? NDA. This seems to be a good enough answer for Red.
Comment by
Redbaron2211 on Apr 16, 2021 12:12pm
Look at the MD&A its clear other indications are going to clinic and this would be reflective of higher spending. I was expecting Hemophilia first but given the focus around thyroid and Dr. Wiseman added to Sernova’s Scientific Advisory Board likely to see thyroid first. If you follow the breadcrumbs its obvious Philip has been a bit busier then some are giving him credit for.
Comment by
Redbaron2211 on Apr 16, 2021 12:30pm
lol, Bio I have made it very clear where I think Philip can improve as CEO. I would rather see him pass over the hammer/nail gun and hire CDO or CMO so he can put more of his energy in R&D ect/.
Comment by
BioTeck on Apr 16, 2021 12:54pm
Glad you finally see the light. He's the kind of CEO i wanted running my 10 million dollar business, not the kind of CEO i want running my half a billion dollar business. He's done well but the role has outgrown him.
Comment by
Redbaron2211 on Apr 16, 2021 1:10pm
It has outgrown him as a one man show and CDO would be welcomed. It's time to build a team and I suspect he's already well on the way. Feedback is helpful but it's only been a few months since they have had the cash to grow into a half a billion dollar business.